Eevia Health publishes Information Memorandum regarding the Rights Issue
NOT FOR PUBLICATION OR DISTRIBUTION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, OR ANY OTHER COUNTRY IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE REQUIRES FURTHER ACTION IN ACCORDANCE WITH THE PREVIOUS STATEMENT OR IS CONTRARY TO THE RULES IN SUCH COUNTRY. DISPUTES ARISING FROM THE CONTENTS OF THE MEMORANDUM OR RELATED LEGAL RELATIONSHIPS SHALL BE SETTLED IN ACCORDANCE WITH SWEDISH LAW AND IN SWEDISH COURTS.
Eevia Health Plc ("Eevia" or "The Company") publishes today an information memorandum by reason of the Rights Issue of shares based on an authorization from the Extraordinary General Meeting held on October 11, 2022, in accordance with the shareholders' pre-emptive subscription right, to issue up new shares with preferential rights in the Company for existing shareholders and the general public in Sweden ("Offer").
The Offer, if fully subscribed, is expected to provide Eevia with SEK 21,6 million before the deduction of expenses related to the Offer. The expected costs are approximately SEK 3 million. The Rights Issue is secured through subscription commitments corresponding to approximately 43 percent of the Offer volume, and underwriting commitments of approximately 39 percent of the Offer volume, resulting in 82 percent in total.
Information memorandum and application form
The information memorandum for the issue is now published on Eevia's website, https://eeviahealth.com, and on Partner Fondkommission AB's website at www.partnerfk.com. An application for the subscription without subscription rights is to be made on the form "Subscription without subscription rights" available for downloading from Partner Fondkommission's website (www.partnerfk.se), at the website of the Company (www.eeviahealth.com), and at Spotlight Stock Market's website (www.spotlightstockmarket.com).
Briefly about the Rights Issue:
- All shareholders registered in Eevia's shareholder register maintained by Euroclear Finland or Euroclear Sweden on the record date of October 27, 2022, will be allocated one (1) subscription right for each share held
- Ten (10) such subscription rights entitle subscription of nine (9) new shares
- Subscription of shares will commence on November 1, 2022, at 09:30 Finnish time (08:30 Swedish time) and is expected to end on November 15, 2022, at 16:30 Finnish time (15:30 Swedish time) in Sweden and on November 17, 2022 at 16:30 Finnish time (15:30 Swedish time) in Finland
- The subscription price is SEK 1,50 (EUR 0,133) per share
- The Company will approximately receive SEK 21,6 million upon full subscription of the Rights Issue
- Trading in subscription rights is ongoing from and including November 1, 2022 until and including November 10, 2022
- Trading in BTA (paid subscription shares) is ongoing from and including November 1, 2022, until the Rights Issue has been registered with the Finnish Trade Register
The Company received, on October 20, 2022, legally binding pre-subscription commitments of approximately SEK 9,3 million, which corresponds to approximately 43 percent of the Offer volume, and underwriting commitments of approximately SEK 8,3 million, which corresponds to approximately 39 percent of the Offer volume, resulting in 82 percent in total.
In association with the Offer as described in this Memorandum, Partner Fondkommission is the financial adviser and issuer agency to Eevia in Sweden, and OP Bank is issuer agent in Finland.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc Joel Westerström, Partner Fondkommission
Telephone: +358 400 22 5967 Telephone: +46 735 11 68 53
IMPORTANT INFORMATION ABOUT THE PRESS RELEASE AND DOCUMENTS
This press release does not constitute an offer to acquire, subscribe to, or otherwise trade in shares, subscription rights, paid subscription shares, or other securities in Eevia Health Plc. Investors must subscribe to or acquire securities only based on the information in the IM, which will be published before the start of the subscription period for the Rights Issue. No action has been taken and no action will be taken to permit an offer to the public in any jurisdiction other than Sweden.
This press release must not be published or distributed, directly or indirectly, to or within Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland, the US, or any other jurisdiction where the distribution of this press release is against the law. Similarly, this press release does not constitute an offer to sell new shares, paid subscription shares, subscription rights, or other securities to anyone in a jurisdiction where it is not allowed to make such an offer to such a person, or where such action would require an additional prospectus, registration, or measures other than those required under Swedish law.
The IM, registration slip, and other documents attributable to the Rights Issue may not be distributed to or within any country where such distribution or Rights Issue requires measures as stated in the preceding sentence, or where this would contravene the law of that country.
No shares, subscription rights, paid subscription shares, or other securities have been registered or will be registered pursuant to the 1933 United States Securities Act in its current version ("the Securities Act") or securities legislation in any state or other jurisdiction of the US, and may not be offered, subscribed to, utilized, pledged, sold, resold, granted, supplied, or otherwise transferred, directly or indirectly, to or within the US, except in accordance with any applicable exemption from or by a transaction that is not covered by the registration requirements of the Securities Act and in accordance with the securities legislation in the relevant state or other jurisdiction of the US.
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.
Om Eevia Health
Eevia Health targets health problems with bioactive extracts from plant material. The human body has an incredible ability to restore good health. However, sometimes the body needs active support. Our mission is to support good health and well-being with plant extracts which have scientifically documented health benefits. Eevia Health manufactures and markets organic ingredients from abundant plant material in the Arctic. Our products are targeted against low-grade inflammation, problems in eye and brain health, and metabolic effects. We collaborate with scientists in Finland and abroad to scientifically substantiate the positive effects of ingredients and also to document the safety of use.